Progenity to Present at 2020 San Antonio Breast Cancer Virtual Symposium

Rhea-AI Summary

Progenity, Inc. (Nasdaq: PROG) will present at the San Antonio Breast Cancer Virtual Symposium (SABCS) from December 8-11, 2020. The presentation is titled Describing the cancer spectrum in families with CHEK2 pathogenic and likely pathogenic variants by mutation type, authored by Julia G Moroney and Michele S. Basiliere. It is scheduled for December 9, 2020, at 8:00 AM CT, with poster number PS8-18. Abstracts will be published in late November 2020, and the poster will be available on the Progenity website after the conference.

SAN DIEGO, Nov. 17, 2020 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing products, will be presenting at the San Antonio Breast Cancer Virtual Symposium (SABCS) set to take place December 8-11, 2020.

The data presented will be a part of the event’s Spotlight Session Poster Presenters. Details of the presentation are as follows:

Title - Describing the cancer spectrum in families with CHEK2 pathogenic and likely pathogenic variants by mutation type
Authors - Julia G Moroney, MS, CGC, and Michele S. Basiliere, MS, CGC
Poster number - PS8-18
Date and time - Wednesday, December 9, 2020: 8:00 AM CT

SABCS anticipates publishing abstracts in late November 2020 and posters on December 9, 2020. The poster presentation will also be made available on the Progenity website following the conference.

About Progenity
Progenity, Inc. is a biotechnology company with an established track record of success in developing and commercializing molecular testing products, as well as innovating in the field of precision medicine. Progenity provides in vitro molecular tests designed to improve lives by providing actionable information that helps guide patients and physicians in making medical decisions during key life stages. The company applies a multi-omics approach, combining genomics, epigenomics, proteomics, and metabolomics to its molecular testing products and to the development of a suite of investigational ingestible devices designed to provide precise diagnostic sampling and drug delivery solutions. Progenity’s vision is to transform healthcare to become more precise and personal by improving diagnoses of disease and improving patient outcomes through localized treatment with targeted therapies. For additional information about Progenity, please visit the company’s website at www.progenity.com.

Investor Contact:
Robert Uhl
Managing Director, Westwicke ICR
ir@progenity.com
(619) 228-5886

Media Contact:
Kate Blom-Lowery
CG Life
media@progenity.com
(619)743-6294

FAQ

What is Progenity presenting at the SABCS 2020?

Progenity is presenting a poster titled 'Describing the cancer spectrum in families with CHEK2 pathogenic and likely pathogenic variants by mutation type' at SABCS 2020.

When will Progenity's presentation take place at the SABCS?

Progenity's presentation is scheduled for December 9, 2020, at 8:00 AM CT.

What is the poster number for Progenity's presentation at SABCS?

The poster number for Progenity's presentation is PS8-18.

Where can I find Progenity's poster after the SABCS?

Progenity's poster will be available on their website following the SABCS conference.

What is the significance of the SABCS for Progenity?

The SABCS provides Progenity a platform to present their research findings in the field of breast cancer genetics, enhancing their visibility in the biotech sector.